Placental Transfer of Anti–Tumor Necrosis Factor Agents in Pregnant Patients With Inflammatory Bowel Disease
Uma Mahadevan(University of California, San Francisco), María T. Abreu(Icahn School of Medicine at Mount Sinai), Thomas Ullman(Montefiore Medical Center), David T. Rubin(University of California System), Sarah C. Glover(Tulane University), Jocelyn Miller(Kaiser Permanente), Antoine Cortot(Centre Hospitalier Universitaire de Lille), Scott D. Lee(University of Washington), John F. Valentine(University of Utah), Corey A. Siegel(Dartmouth–Hitchcock Medical Center), Douglas C. Wolf(Atlanta Gastroenterology Associates), Marla C. Dubinsky(Icahn School of Medicine at Mount Sinai)
Cited by 492
Related Papers
Host–microbe interactions have shaped the genetic architecture of inflammatory bowel disease
|Nature|2012|4.8k
STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD
|Gastroenterology|2021|2.6k
Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci
|Nature Genetics|2010|2.6k
Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target
|The American Journal of Gastroenterology|2015|1.8k
ACG Clinical Guideline: Ulcerative Colitis in Adults
|The American Journal of Gastroenterology|2019|1.6k